Literature DB >> 28704277

Effects of ceftriaxone on conditioned nicotine reward in rats.

Helene L Philogene-Khalid1, Steven J Simmons, John W Muschamp, Scott M Rawls.   

Abstract

Nicotine is the addictive compound in tobacco products which exerts psychosomatic effects that contribute to abuse and to low rates of abstinence in treatment-seeking smokers. At present, the most successful smoking cessation aide helps one in four individuals quit smoking at 1 year postcessation. New adjunctive therapies are needed to improve status of smoking-related public health crises, and β-lactam antibiotics are one class of potential therapies as they favorably augment extrasynaptic glutamate clearance. Our study used two-chamber place conditioning to assess effects of ceftriaxone (CTX) on persistence of conditioned nicotine reward. Rats were conditioned to associate nicotine (0.4 mg/kg, subcutaneous) with one context and vehicle with an alternative context. After initial post-test, rats received either daily ceftriaxone (200 mg/kg, intraperitoneal) or saline. All rats showed nicotine place preference during post-test 1. CTX-treated rats meeting extinction criterion by post-test 7 showed significantly reduced preference for the nicotine-paired context during post-test 2 compared with vehicle-treated rats. We interpret these data to support the further study of CTX as a smoking cessation aide. Our results suggest that CTX reduces persistence of conditioned nicotine reward and may be helpful for improving abstinence rates in a subset of treatment-seeking smokers.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28704277      PMCID: PMC5538934          DOI: 10.1097/FBP.0000000000000314

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN: 0955-8810            Impact factor:   2.293


  23 in total

1.  Upregulation of surface alpha4beta2 nicotinic receptors is initiated by receptor desensitization after chronic exposure to nicotine.

Authors:  C P Fenster; T L Whitworth; E B Sheffield; M W Quick; R A Lester
Journal:  J Neurosci       Date:  1999-06-15       Impact factor: 6.167

2.  Pentameric structure and subunit stoichiometry of a neuronal nicotinic acetylcholine receptor.

Authors:  E Cooper; S Couturier; M Ballivet
Journal:  Nature       Date:  1991-03-21       Impact factor: 49.962

Review 3.  Brain nicotinic acetylcholine receptors: native subtypes and their relevance.

Authors:  Cecilia Gotti; Michele Zoli; Francesco Clementi
Journal:  Trends Pharmacol Sci       Date:  2006-07-31       Impact factor: 14.819

4.  Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial.

Authors:  Douglas E Jorenby; J Taylor Hays; Nancy A Rigotti; Salomon Azoulay; Eric J Watsky; Kathryn E Williams; Clare B Billing; Jason Gong; Karen R Reeves
Journal:  JAMA       Date:  2006-07-05       Impact factor: 56.272

5.  Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression.

Authors:  Jeffrey D Rothstein; Sarjubhai Patel; Melissa R Regan; Christine Haenggeli; Yanhua H Huang; Dwight E Bergles; Lin Jin; Margaret Dykes Hoberg; Svetlana Vidensky; Dorothy S Chung; Shuy Vang Toan; Lucie I Bruijn; Zao-Zhong Su; Pankaj Gupta; Paul B Fisher
Journal:  Nature       Date:  2005-01-06       Impact factor: 49.962

6.  Glutamate transporter activation enhances nicotine antinociception and attenuates nicotine analgesic tolerance.

Authors:  Joseph A Schroeder; Katrina F Quick; Paige M Landry; Scott M Rawls
Journal:  Neuroreport       Date:  2011-12-21       Impact factor: 1.837

7.  Effects of ceftriaxone on ethanol, nicotine or sucrose intake by alcohol-preferring (P) rats and its association with GLT-1 expression.

Authors:  Youssef Sari; Jamie E Toalston; P S S Rao; Richard L Bell
Journal:  Neuroscience       Date:  2016-04-07       Impact factor: 3.590

8.  The beta-lactam antibiotic, ceftriaxone, attenuates morphine-evoked hyperthermia in rats.

Authors:  S M Rawls; R Tallarida; W Robinson; M Amin
Journal:  Br J Pharmacol       Date:  2007-06-25       Impact factor: 8.739

9.  Effects of the beta-lactam antibiotic ceftriaxone on nicotine withdrawal and nicotine-induced reinstatement of preference in mice.

Authors:  M Alajaji; M S Bowers; L Knackstedt; M I Damaj
Journal:  Psychopharmacology (Berl)       Date:  2013-03-16       Impact factor: 4.530

10.  Clavulanic acid enhances glutamate transporter subtype I (GLT-1) expression and decreases reinforcing efficacy of cocaine in mice.

Authors:  Jae Kim; Joel John; Dianne Langford; Ellen Walker; Sara Ward; Scott M Rawls
Journal:  Amino Acids       Date:  2015-11-05       Impact factor: 3.520

View more
  3 in total

1.  Evidence for Modulation of Substance Use Disorders by the Gut Microbiome: Hidden in Plain Sight.

Authors:  Mariana Angoa-Pérez; Donald M Kuhn
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468

Review 2.  Ceftriaxone as a Novel Therapeutic Agent for Hyperglutamatergic States: Bridging the Gap Between Preclinical Results and Clinical Translation.

Authors:  Osama A Abulseoud; Fawaz Alasmari; Abdelaziz M Hussein; Youssef Sari
Journal:  Front Neurosci       Date:  2022-07-05       Impact factor: 5.152

Review 3.  Involvement of extrasynaptic glutamate in physiological and pathophysiological changes of neuronal excitability.

Authors:  Balázs Pál
Journal:  Cell Mol Life Sci       Date:  2018-05-15       Impact factor: 9.261

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.